Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TOP1 | P11387 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77406 | 0.87 | MAPT (0.43) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL4468025 | 0.82 | MAPT (0.65) | ALDH1A1LMNAMAPTMAPK1TDP1 | |
| SCHEMBL3750305 | 0.82 | MAPT (0.46) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL77294 | 0.81 | HSD17B10 (0.47) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL76589 | 0.80 | ALDH1A1 (0.45) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL3676602 | 0.79 | MAPT (0.42) | ALDH1A1LMNAMAPTSMN1; SMN2GAA | |
| SCHEMBL85665 | 0.79 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL209737 | 0.78 | MAPT (0.67) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL29822510 | 0.78 | MAPT (0.67) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL5652989 | 0.77 | MAPT (0.45) | ALDH1A1LMNAMAPTMAPK1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| EP-1720844-B1 | PYRROLIDINO-1,2-DICARBOXY-1-(PHENYLAMIDE)-2-(4-(3-OXO-MORPHOLINO-4-YL)-PHENYLAMIDE) DERIVATIVES AND RELATED COMPOUNDS FOR USE AS INHIBITORS OF COAGULATION FACTOR XA IN THE TREATMENT OF THROMBO-EMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080081814-A1 | Carbonyl Compounds Which Can be Used as Inhibitors of Coagulation Factor Xa | CEZANNE BERTRAM | 2008-04-03 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20070265259-A1 | Proline Derivatives | MERCK PATENT GMBH (DE) | 2007-11-15 | — | — | US | disclosed |
| EP-1797071-A1 | CARBONYL COMPOUNDS USABLE AS COAGULATION FACTOR XA INHIBITORS | Merck Patent GmbH (DE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1797079-A1 | PROLINE DERIVATIVES | Merck Patent GmbH (DE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1791597-A2 | CARBONYL COMPOUND-CONTAINING DRUG AND THE USE THEREOF | Merck Patent GmbH (DE) | 2007-06-06 | — | — | EP | disclosed |
| EP-1720844-A2 | PYRROLIDINO-1,2-DICARBOXY-1-(PHENYLAMIDE)-2-(4-(3-OXO-MORPHOLINO-4-YL)-PHENYLAMIDE) DERIVATIVES AND RELATED COMPOUNDS FOR USE AS INHIBITORS OF COAGULATION FACTOR XA IN THE TREATMENT OF THROMBO-EMBOLIC DISEASES | MERCK PATENT GmbH (DE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060183739-A1 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
| WO-2006034789-A1 | PROLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006034769-A1 | CARBONYL COMPOUNDS USABLE AS COAGULATION FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006032342-A2 | CARBONYL COMPOUND-CONTAINING DRUG AND THE USE THEREOF | MERCK PATENT GMBH (DE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2004087646-A2 | PYRROLIDINO-1,2-DICARBOXY-1-(PHENYLAMIDE)-2-(4-(3-OXO-MORPHOLINO-4-YL)-PHENYLAMIDE) DERIVATIVES AND RELATED COMPOUNDS FOR USE AS INHIBITORS OF COAGULATION FACTOR XA IN THE TREATMENT OF THROMBO-EMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265259-A1 | Proline Derivatives | F2, XPNPEP1, PRAP1 | ALDH1A1 1828/4885LMNA 1029/4885MAPT 4809/4885 |
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | ALDH1A1 268/4885LMNA 918/4885MAPT 3896/4885 |
| US-20080081814-A1 | Carbonyl Compounds Which Can be Used as Inhibitors of Coagulation Factor Xa | F2, F11, F12 | ALDH1A1 593/4885LMNA 866/4885MAPT 4368/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | ALDH1A1 339/4885LMNA 626/4885MAPT 2660/4885 |
| US-20060183739-A1 | Carbonyl compounds | F2, F11, PDHX | ALDH1A1 268/4885LMNA 918/4885MAPT 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.